Adding Cyclophosphamide to Standard Prostate Cancer Therapy Provides No Benefit

Share this content:
Adding cyclophosphamide to docetaxel and prednisone for treatment of CRPC does not seem to provide any additional benefit.
Adding cyclophosphamide to docetaxel and prednisone for treatment of CRPC does not seem to provide any additional benefit.

Adding cyclophosphamide to docetaxel and prednisone for treatment of castration-resistant prostate cancer (CRPC) does not seem to provide any additional benefit, according to a German study published in Chemotherapy.

In a randomized, multicenter phase II trial, researchers led by Markus Porsch, MD, looked at 33 patients who received six 3-week treatment cycles of either the standard therapy of docetaxel and prednisone, or standard therapy with cyclophosphamide.

RELATED: Vaccine with Sequential Androgen Ablation Therapy Shows Promise in Prostate Cancer

The researchers found no significant differences between the two groups in terms of blood pressure, weight, pain score, laboratory variables and quality of life.

There was an adequate decline in PSA levels in both groups, with no difference in decline in either group.

“An additional effect of cyclophophamide was not detected,” the authors concluded. “However, the small number of patients and short observation period restrict the generalisability of the results.”

Reference

  1. Porsch, M., et al. "A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer." Chemotherapy. DOI:10.1159/000369781. February 26, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs